Results 111 to 120 of about 21,798 (199)

Sequential Analysis of Murine Myelofibrosis Models Using a Novel Deep Learning-Based Fibrosis Quantitative Method. [PDF]

EJHaem
Kawamura T, Maekawa T, Kouzu K, Ogata H, Tachi N, Kato S, Osawa Y, Einama T, Sato K, Kobayashi S.   +9 more
europepmc   +1 more source

Myelofibrosis

, 2020
openaire   +2 more sources

Hydroxyurea-Associated Wunderlich Syndrome in Triple-Negative Myelofibrosis: A Case Report and Literature Review. [PDF]

Case Rep Hematol
Erol V, Güzel Z, Akgün İE, Ecer G.
europepmc   +1 more source

Real-world prevalence and outcome of elevated right ventricular systolic pressure in myelofibrosis. [PDF]

Cardiooncology
Sharma AB, Wang E, Selvakumar S, Koelmeyer H, Shetty S, Buckley K, Mo Q, Smith T, Chao A, Balen C, Mannam G, Yudiono J, Lien K, Khatib S, Paduchuri V, Al Ali N, Song J, Nishihori T, Lancet JE, Alomar M, Cleveland JL, Kuykendall A, Komrokji RS, Yun S, Lee DH.   +24 more
europepmc   +1 more source

Correction: Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial. [PDF]

Bone Marrow Transplant
Van Dijck R, van der Holt B, Broers AEC, Hazenberg MD, Devos T, van der Poel MWM, Breems D, Deleu L, Schuthof BAG, van Hooije CMC, Cornelissen JJ, Schaap NPM, Te Boekhorst PAW.   +12 more
europepmc   +1 more source

Connective tissue diseases combined with chronic myelomonocytic leukemia and myelofibrosis: a case report and literature review. [PDF]

Front Immunol
Yin HQ, Jin S, Fu Y, Zhu HL, Li XF.
europepmc   +1 more source

Cardiac Tamponade-A Rare Manifestation of Ruxolitinib Discontinuation Syndrome: A Case Report. [PDF]

Case Rep Cardiol
Hamid S, Bennet R, Yao J, Wong J.
europepmc   +1 more source

Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis: Results From the Phase 2 XPORT-035 Study. [PDF]

EJHaem
Grosicki S, Yimer H, Ayala R, Chen S, Liu H, Boyer F, Guglielmelli P, Brociner M, Sportoletti P, Mikala G, Tsirigotis P, Zhang J, Mark T, Chai Y, Ellero A, Lucchesi A.   +15 more
europepmc   +1 more source

High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohort. [PDF]

Ann Hematol
Mendicino F, Caridà G, Bruzzese A, Martino EA, Caserta S, Amodio N, Lucia E, Olivito V, Labanca C, Alvaro ME, Luciani F, Morabito F, Vigna E, Gentile M.   +13 more
europepmc   +1 more source

Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review. [PDF]

Front Oncol
Al-Asa'd Y, Qasem N, Alshurafa A, Al-Farsi K, Yassin MA.   +4 more
europepmc   +1 more source